Wu Chen, Li Xiang, Liu Shiyang, Yao Litong, He Tianyi, Wang Yusong, Dong Haoran, Niu Shuyi, Wang Mozhi, Xu Yingying
Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning Province 110001, China.
iScience. 2024 Oct 31;27(12):111224. doi: 10.1016/j.isci.2024.111224. eCollection 2024 Dec 20.
Whether patients with metastatic breast cancer ( MBC) benefit from primary tumor resection (PTR) is controversial, and the efficacy of treatment of primary tumor in patients with oligometastases is uncertain. A comprehensive search was conducted for studies published from January 1, 2008 to January 1, 2024 that compared PTR with no PTR for MBC that quantified the extent of metastasis. Ten studies and 83,559 patients with MBC were included. A meta-analysis showed a significant improvement in overall survival after PTR compared with no PTR (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.53-0.67; < 0.00001). Similar results were seen in patients with 1 metastatic organ, ≤2 metastatic organs, and ≤3 metastatic organs. Oligometastatic patients are expected to be a beneficial subgroup for PTR in patients with MBC, especially when metastasis occurs in only one organ.
转移性乳腺癌（MBC）患者是否能从原发性肿瘤切除（PTR）中获益存在争议，且寡转移患者的原发性肿瘤治疗效果尚不确定。我们全面检索了2008年1月1日至2024年1月1日发表的研究，这些研究比较了PTR与未进行PTR治疗MBC且对转移程度进行量化的情况。纳入了10项研究和83559例MBC患者。荟萃分析显示，与未进行PTR相比，PTR后总生存期有显著改善（风险比[HR]，0.60；95%置信区间[CI]，0.53 - 0.67；P < 0.00001）。在有1个转移器官、≤2个转移器官和≤3个转移器官的患者中也观察到了类似结果。预计寡转移患者是MBC患者中PTR的一个有益亚组，尤其是当转移仅发生在一个器官时。
